drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A human afucosylated IgG1 monoclonal antibody (AMG 451/KHK4083) targeting OX40 (CD134). It blocks OX40–OX40L signaling to reduce T‑cell activation, proliferation, survival, and cytokine production, and enhances ADCC-mediated depletion of OX40+ T cells; administered subcutaneously for atopic dermatitis.
nci_thesaurus_concept_id
C184936
drug_mesh_term
Rocatinlimab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Rocatinlimab is a human afucosylated IgG1 monoclonal antibody that binds OX40 (CD134), blocking OX40–OX40L costimulatory signaling to suppress T‑cell activation, proliferation, survival, and cytokine production. Its afucosylated Fc enhances ADCC, promoting depletion of OX40+ activated/memory T cells, thereby reducing inflammatory responses in atopic dermatitis.
drug_name
Rocatinlimab
nct_id_drug_ref
NCT05633355